MicuRx Pharmaceuticals, Inc.
  • About MicuRx
    • Our company
    • Our Team
    • Vision & mission
    • History
    • Contact Us
  • Scientific research
    • Antibiotic Resistance
    • Kidney Disease
    • MicuRx R&D
    • Publications
  • Pipeline
  • Newsroom
    • Corporate news
  • Careers
  • Contact Us
  • 中
  • Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs

    Time:2024-01-31  /  View:370 times
    Prev: Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
    Next: Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
    Back

    Copyright © 2025 All Rights Reserved MicuRx

    Medical Representative Recordation Platform 沪ICP备12020812号

    MicuRx Pharmaceuticals, Inc.